Takeda’s Zasocitinib Demonstrates Landmark Phase 3 Results in Plaque Psoriasis, Offering Hope for Clear Skin with a Once-Daily Oral Therapy and Ushering in a New Treatment Era Takeda today announced positive topline results for the two pivotal Phase 3 randomized,…
Lilly’s Orforglipron Helps Sustain Weight Loss After Switching from Injectable to Oral GLP-1 Therapy in Pivotal Phase 3 Trial Eli Lilly and Company today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational,…
CDC Officially Approves Delayed Hepatitis B Vaccine Dose The CDC has accepted the recommendation of its vaccine advisory committee and ended the three-decade-long practice of giving most newborn children a birth dose of the hepatitis B vaccine.The change in recommendation, announced Tuesday, leaves the…
Argenx Shares Update on UplighTED Clinical Trials of Subcutaneous Efgartigimod for Thyroid Eye Disease Argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies…
Merck Receives Positive CHMP Opinion in the EU for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH; WHO Group 1 Pulmonary Hypertension) Merck, known as MSD outside of the United States and Canada, today announced that…
Bio-Techne Collaborates with Wyss Center Geneva to Drive Innovation in Automated 3D Multiomics and Accelerate Spatial Biology Research Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced a strategic collaboration between one of its…
ICON plc, a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in…
Phase 3 MajesTEC-3 Study Delivers Unprecedented Results, Positioning TECVAYLI® Plus DARZALEX FASPRO® as a Potential New Standard of Care as Early as Second-Line Treatment for Relapsed/Refractory Multiple Myeloma Johnson & Johnson, the worldwide leader in multiple myeloma, today announced new…
Johnson & Johnson’s INLEXZO™ (Gemcitabine Intravesical System) Achieves 74% Disease-Free Survival at One Year in Patients with BCG-Unresponsive, High-Risk, Papillary-Only NMIBC Johnson & Johnson announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study…
Bayer Launches Phase IIa Clinical Trial of Novel Therapy for Alport Syndrome Bayer has announced the initiation of a Phase IIa clinical trial evaluating BAY 3401016, an investigational monoclonal antibody designed to inhibit Semaphorin 3A (Sema3A)—a protein increasingly implicated in…
Bristol Myers Squibb Advances ADEPT-2 Phase 3 Trial for Alzheimer’s-Related Psychosis Following Rigorous Data Review and FDA Alignment Bristol Myers Squibb has announced a significant update regarding its ADEPT-2 Phase 3 clinical study, designed to evaluate the efficacy and safety…
Lilly and Indiana University Forge Historic $40 Million Partnership to Revolutionize Clinical Trials and Expand Access to Cutting-Edge Therapies for Hoosiers Eli Lilly and Company and Indiana University (IU) have announced a transformative five-year partnership valued at up to $40…